| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_87665e71c7262a1d1deffa8baa53c23b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ee85cef0848226aacf128c14bfc57aae |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-002 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-90 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P33-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-002 |
| filingDate |
2021-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be577fe2e02dce0d6801a4fe4b70504c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b39942bb1eac72cde7d53c51039188e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af06f43ae11bd4742b1ad1756cde431d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2003b26b90900034cbbc76ea47fec38f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e11966f0b9393fffe46b1769e718564
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40b0f85fa5d403117e727c314485df3d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_720515df3227fd93c8ae8ccb1d373903 |
| publicationDate |
2022-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-114164114-A |
| titleOfInvention |
Toxoplasma gondii ribulose-5-phosphate isomerase TgRPI gene editing strain and its application |
| abstract |
Toxoplasma gondii ribulose-5-phosphate isomerase TgRPI gene editing strain and its application. The invention discloses a potential vaccine and drug design target and a gene knockout strain for preventing Toxoplasma gondii infection. The vaccine and drug design target is Toxoplasma gondii ribulose-5-phosphate isomerase TgRPI gene, and its nucleotide sequence is shown in SEQ ID NO: 2. The gene knockout worm strain has knocked out the TgRPI gene, and the gene knockout worm strain has slowed growth rate in vitro, but can be subcultured, has characteristics such as low virulence and less reproduction in animals, and can improve the immunity of animals to Toxoplasma gondii ability. Because TgRPI plays an important role in the growth of Toxoplasma gondii in vitro and in vivo, it has the potential to become a vaccine and drug target, and the gene knockout strain has the potential to become a genetically engineered vaccine against Toxoplasma gondii. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114933970-A |
| priorityDate |
2021-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |